The race to find the next blockbuster medicine has biotech investors studying two price tags: what a treatment could earn and what a larger drugmaker might pay to take it home. Patent expirations are encouraging pharmaceutical companies to replenish their pipelines before their biggest sellers start sharing shelf space with cheaper competition. Meanwhile, advances in obesity, oncology, and other treatment areas are attracting capital. The difficult part remains separating a promising investment from an expensive science project with excellent presentation slides.
Big Pharma Goes Shopping Before the Patents Expire
The acquisition spree was already gathering speed early in 2026. In a May 1 report, Reuters cited Dealogic figures showing first-quarter biotech deal value of $84 billion, up from $44.4 billion a year earlier. Pharmaceutical companies were clearly doing more than adding items to their wish lists.
The same report cited a William Blair estimate that more than $300 billion in industry revenue faced losses of exclusivity over the following five years. That gives drugmakers a substantial reason to shop. A blockbuster medicine can support years of earnings, but its patent protection does not come with a lifetime membership.
By July, the shopping carts had become noticeably heavier. The Financial Times reported on July 21 that 37 biotech acquisitions worth at least $1 billion had been announced that year, already exceeding the previous full-year record of 35, according to Stifel. Separately, LSEG data cited in the report put biotech deal value at $216 billion, compared with $118 billion over the corresponding period in 2025.
Buyers Want Medicines That Can Start Paying the Bills
For investors, what sits inside an acquisition matters as much as the number of zeros attached to it. The Financial Times described growing interest in businesses with revenue-generating medicines or treatments approaching launch. Buyers facing patent expirations have good reason to prefer products that can contribute soon. “Potentially exciting in several years” becomes a harder pitch when a major revenue stream has an approaching expiration date.
Earlier-stage developers still offer opportunities, but their medicines require more time, money, and clinical evidence. A credible takeover thesis therefore needs differentiated science, a realistic development timetable, and enough financial strength to keep operating if the hoped-for buyer never calls. Waiting for an acquisition should not become the entire business plan.
The buyer’s arithmetic also deserves attention. Our analysis of Biogen examines how pipeline acquisitions can improve a growth outlook while adding earnings charges and execution risk. Buying a promising asset may fill a pipeline gap, but the purchase receipt is not proof of stronger shareholder returns.
Weight-Loss Drugs Attract Heavyweight Expectations
Obesity remains a prominent battleground. A September 30 Reuters overview cited analyst expectations that the weight-loss market could approach $100 billion in annual sales over the next decade. The treatments may be designed to reduce weight, but expectations for the market are carrying very little restraint.
Developers are pursuing pills, less frequent injections, and treatments that preserve lean mass. Those differences could matter commercially, provided clinical results translate into practical benefits for patients, physicians, and payers. A medicine still needs reimbursement, affordable access, and a defensible place in the market. An impressive demand forecast does not automatically persuade an insurer to pick up the bill.
An August 28 Financial Times report highlighted another complication through counterfeit weight-loss treatments in the UK. Novo Nordisk had secured an expanded website-blocking order, while Eli Lilly was disrupting online sellers of unlicensed products.
That adds an unwelcome item to the commercialization checklist. Developing an effective medicine is difficult enough without counterfeit sellers attempting to join the launch. Trusted distribution and product integrity help protect both legitimate patient access and confidence in the treatment.
The Science Needs Funding and the Stock Needs a Sensible Price
Valuation and financial resilience remain essential across biotechnology. Profitable companies can be assessed against earnings and cash flow. Clinical-stage developers require closer examination of cash reserves, spending, and potential shareholder dilution. A compelling pipeline needs enough funding to reach its next milestone; enthusiasm has yet to qualify as legal tender.
Our earlier coverage of Viking Therapeutics connects the progress of its obesity pipeline with the cash available to fund further development, illustrating why clinical milestones and financial resources belong in the same assessment.
Billionaire ownership can highlight stocks attracting experienced investors, but even a famous name on the shareholder register cannot negotiate with a clinical endpoint. The stronger investment candidates combine differentiated science, sufficient funding, and a purchase price that leaves room for setbacks. A successful trial or takeover can improve the story considerably. The investment case should still have something to say if neither arrives on schedule.
CHECK THIS OUT: 10 Best Biotech Stocks Under $10 to Buy Now and Top 6 Small-Cap Healthcare Stocks to Buy Right Now.
Our Methodology
To identify the 10 best biotech stocks to buy according to billionaires, we reviewed financial media sources and stock screeners for U.S.-listed biotechnology companies, selected the 10 with the most bullish billionaire positions in our Q2 2026 holdings database, and ranked them in ascending order by the number of billionaire holders.
10 Best Biotech Stocks to Buy According to Billionaires
10. Prime Medicine Inc. (NASDAQ:PRME)
Number of Hedge Fund Holders — 28
Number of Billionaire Holders — 17
Prime Medicine, Inc. (NASDAQ: PRME) has made progress on two fronts that matter to biotechnology investors: securing the right to develop its medicines and advancing those medicines into clinical trials.
In July, a binding arbitration decision confirmed that PM647, its investigational treatment for alpha-1 antitrypsin deficiency, falls within its permitted development field under an existing collaboration agreement. The tribunal determined that the company had not breached that agreement and owed no monetary damages. That removed a legal obstacle, although the treatment’s clinical prospects still require human evidence.
The program subsequently advanced. On September 24, the company announced FDA clearance of its investigational new drug application for PM647, enabling clinical testing in the United States. The candidate is designed to correct a disease-causing mutation associated with both liver and lung complications, with initial clinical data expected in 2027.
A separate milestone arrived on October 5, when the company reported dosing the first patient in its global Phase 1/2 study of PM577a for H1069Q-mutated Wilson disease. The investigational treatment aims to correct an underlying genetic defect through a single administration.
“Dosing the first patient with PM577a is a meaningful step toward our goal,” CEO Allan Reine said in the announcement.
The balance sheet deserves equal attention. Cash, cash equivalents, investments, and restricted cash totaled $108.8 million at June 30, with management projecting funding into 2027. That makes the relationship between clinical timelines and financing needs particularly relevant.
For investors researching gene-editing stocks, the next test is whether regulatory clearances translate into convincing safety and efficacy findings. Permission to begin a trial opens the door; the results determine what lies behind it.
Ranking rationale: Prime Medicine, Inc. (NASDAQ: PRME) ranks tenth with 17 billionaire holders. Its expanding clinical pipeline and resolution of the PM647 dispute support its inclusion, while its comparatively limited financial runway keeps funding execution central to the investment case.
